Immunobiology of cholangiocarcinoma

Tomlinson, Jennifer L.; Valle, Juan W; Ilyas, Sumera

doi:10.1016/j.jhep.2023.05.010

Cited by 23 publications

(9 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ICCA, the TIME plays a crucial role in tumor growth, invasion, angiogenesis, and metastasis through its interactions with tumor cells [227]. Recent studies have identified novel TIME-based subtypes of CCA, each characterized by distinct mechanisms of immune escape and patient outcomes [228]. However, the immunobiology, antitumor immunity, and immunotherapy for ICCAs are still poorly understood.…”

Section: Future Perspectivesmentioning

confidence: 99%

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Choi,

Thung

2024

Preprint

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICCA) is a malignant epithelial neoplasm characterized by biliary differentiation within the liver. ICCA is molecularly heterogeneous and exhibits a broad spectrum of histopathological features. It is a highly aggressive carcinoma with high mortality and poor survival rates. ICCAs are classified into two main subtypes: small duct type and large duct types. These two tumor types have different cell origins and clinicopathological features. ICCAs are characterized by numerous molecular alterations, including mutations in KRAS, TP53, IDH1/2, ARID1A, BAP1, BRAF, SAMD4, and EGFR, and FGFR2 fusion. Two main molecular subtypes–inflammation and proliferation–have been proposed. Recent advances in high-throughput assays using next-generation sequencing have improved our understanding of ICCA pathogenesis and molecular genetics. The diagnosis of ICCA poses a significant challenge for pathologists because of its varied morphologies and phenotypes. Accurate diagnosis of ICCA is essential for effective patient management and prognostic determination. This article provides an updated overview of ICCA pathology, focusing particularly on molecular features, histological subtypes, and diagnostic approaches.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Choi,

Thung

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…78 MiR-206 suppression is implicated in CCA, and its reduction is linked to the transformation of the CAF phenotype. 79…”

Section: Roles Of Tumor Immune Microenvironment In Icc Recruitment An...mentioning

confidence: 99%

Igniting cold tumors of intrahepatic cholangiocarcinoma: An insight into immune evasion and tumor immune microenvironment

Zhou,

Zhang,

et al. 2024

TIME

View full text Add to dashboard Cite

<p>Intrahepatic cholangiocarcinoma (ICC) is a rare hepatobiliary cancer that originates from the epithelium of the intrahepatic bile duct. The various treatments for ICC, such as chemotherapy, radiotherapy, and locoregional therapy, confer only modest improvements in survival rates. Immunotherapy, although revolutionary in cancer treatment, has found limited application in the treatment of ICCs due to the ��cold�� nature of these tumors, which is marked by scant T-cell infiltration. This characteristic makes immune checkpoint inhibitors (ICIs) unsuitable for the majority of ICC patients. Therefore, comprehensively understanding the mechanisms underlying these ��cold�� tumors is crucial for harnessing the potential of immunotherapy for treating ICC patients. This paper explores immune evasion mechanisms and the complex tumor immune microenvironment of ICC. This study provides a comprehensive overview of therapeutic strategies aimed at activating cold tumors and enhancing their immunogenicity. Furthermore, potential and promising targets for cancer vaccines and adoptive cellular therapy in the context of ICC are discussed. This endeavor strives to reveal new pathways for innovative immunotherapy strategies, with a focus on overcoming the key challenge of triggering an effective immune response in ICC patients.</p>

show abstract

“…This is largely due to its aggressive invasion and the limited availability of efficacious treatment options (Roa et al, 2022). CCA is characterized as a highly lethal and heterogeneous primary liver cancer that originates from the biliary epithelium (Tomlinson et al, 2023;Ilyas et al, 2023). The incidence of BTC is on an upward trajectory globally, btc continues to constitute a significant global health concern.…”

Section: Introductionmentioning

confidence: 99%

The causal relationship between gut microbiota and biliary tract cancer: comprehensive bidirectional Mendelian randomization analysis

Wang,

Qin

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundGrowing evidence has shown that gut microbiome composition is associated with Biliary tract cancer (BTC), but the causality remains unknown. This study aimed to explore the causal relationship between gut microbiota and BTC, conduct an appraisal of the gut microbiome’s utility in facilitating the early diagnosis of BTC.MethodsWe acquired the summary data for Genome-wide Association Studies (GWAS) pertaining to BTC (418 cases and 159,201 controls) from the Biobank Japan (BBJ) database. Additionally, the GWAS summary data relevant to gut microbiota (N = 18,340) were sourced from the MiBioGen consortium. The primary methodology employed for the analysis consisted of Inverse Variance Weighting (IVW). Evaluations for sensitivity were carried out through the utilization of multiple statistical techniques, encompassing Cochrane’s Q test, the MR-Egger intercept evaluation, the global test of MR-PRESSO, and a leave-one-out methodological analysis. Ultimately, a reverse Mendelian Randomization analysis was conducted to assess the potential for reciprocal causality.ResultsThe outcomes derived from IVW substantiated that the presence of Family Streptococcaceae (OR = 0.44, P = 0.034), Family Veillonellaceae (OR = 0.46, P = 0.018), and Genus Dorea (OR = 0.29, P = 0.041) exerted a protective influence against BTC. Conversely, Class Lentisphaeria (OR = 2.21, P = 0.017), Genus Lachnospiraceae FCS020 Group (OR = 2.30, P = 0.013), and Order Victivallales (OR = 2.21, P = 0.017) were associated with an adverse impact. To assess any reverse causal effect, we used BTC as the exposure and the gut microbiota as the outcome, and this analysis revealed associations between BTC and five different types of gut microbiota. The sensitivity analysis disclosed an absence of empirical indicators for either heterogeneity or pleiotropy.ConclusionThis investigation represents the inaugural identification of indicative data supporting either beneficial or detrimental causal relationships between gut microbiota and the risk of BTC, as determined through the utilization of MR methodologies. These outcomes could hold significance for the formulation of individualized therapeutic strategies aimed at BTC prevention and survival enhancement.

show abstract

Immunobiology of cholangiocarcinoma

Cited by 23 publications

References 81 publications

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Igniting cold tumors of intrahepatic cholangiocarcinoma: An insight into immune evasion and tumor immune microenvironment

The causal relationship between gut microbiota and biliary tract cancer: comprehensive bidirectional Mendelian randomization analysis

Contact Info

Product

Resources

About